Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

How to Ask the Right Questions at an Authority Meeting

As a drug developer, you have to live with the answers and comments you get from regulatory authorities. Therefore, it’s essential that you choose your questions carefully and avoid questions you don’t need answers to. Here we take a closer look at how to approach these meetings.

Read full article

Perspectives on Enquiry and Evidence

November 3, 2022

Cytel at ISPOR Europe: Two Workshops

Cytel will be represented at over 60 presentations at ISPOR Europe 2022, with more issue panels and workshops than any...

Read article

October 27, 2022

The Need for a “Living” Approach to HTAs

Read article

October 21, 2022

Balancing Real-World Data Quality vs. Locality

Read article

October 20, 2022

The Need for Structured Tools to Guide HTA Submissions

Read article

October 13, 2022

Cytel at ISPOR Europe: Top Presenter of Issue Panels and Workshops

ISPOR Europe, the leading global conference for health economics and outcomes research (HEOR) and real-world evidence...

Read article

September 15, 2022

U.S. Drug Pricing Reform: Potential Impact on Pharma HEOR Evidence Generation

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes U.S. drug...

Read article

August 4, 2022

Interview with Allison Luccock about career perspectives

In this edition of the Career Perspectives series, I interview Allison Luccock, Director of Business Operations for...

Read article

May 27, 2022

How to Use a Living HTA Approach to Demonstrate Value in Real-Time

When submitting systematic literature reviews to a Health Technology Assessment authority, high volumes of research...

Read article

May 5, 2022

Interview with Grammati Sarri on Moderating an Issue Panel 2022

While randomized control trials remain the industry gold-standard for regulatory and reimbursement submissions, there...

Read article

May 4, 2022

Optimizing Human-Machine Partnership for Up-To-Date Evidence

If you are a pharmaceutical or biotech company seeking to enter the market with a new drug, you need to submit a...

Read article

April 29, 2022

An Interview with Gabriel Tremblay on his Poster Contributions to ISPOR US 2022

At ISPOR US 2022, Cytel’s HEOR & RWE experts will be contributing to a range of Issue Panels, In-person Podium...

Read article

April 22, 2022

Cytel’s Single Arm Trials Panel Selected as a Part of ISPOR 2022

This past decade has undoubtedly witnessed an increase in the number of single arm trials submitted to HTA bodies....

Read article

April 13, 2022

Join Cytel’s HEOR Consultants at ISPOR US 2022

The Life Sciences landscape has seen an impactful digital evolution in the past two years. The pandemic has accelerated...

Read article

November 23, 2021

Using Single Arm Trials for HTA Submissions: Dr. Heeg and Maria Rizzo

A randomized clinical trial (RCT) is the gold standard approach to demonstrate the efficacy and safety of novel...

Read article

November 11, 2021

Championing RWE & HEOR at Virtual ISPOR Europe 2021

The value of Real World Evidence (RWE) is well known to many stakeholders, but its full potential for market access and...

Read article

November 4, 2021

Join Cytel for HEOR Insights at ISPOR Europe 2021

The prominent European conference for Health Economics and Outcomes Research (HEOR), ISPOR Europe 2021, is around the...

Read article

May 13, 2021

An Interview with Radek Wasiak, Head of Real World and Advanced Analytics at Cytel

Cytel’s HEOR and RWE Expertise has grown quite significantly in the past year. Could you speak a little bit about the...

Read article

May 5, 2021

Meet our Global HEOR and RWE Experts: Virtual ISPOR 2021

Cytel’s team of HEOR and RWE experts are all set to make a splash at the Virtual ISPOR on May 17 - 20. Our global...

Read article

April 29, 2021

Advances in HEOR: An Interview with Anna Forsythe

After twenty years in pharma, Anna Forsythe was frustrated by traditional vendors who used outdated methods to prepare...

Read article

November 24, 2020

Cytel and Ingress Health at Virtual ISPOR Europe 2020

Virtual ISPOR 2020, held November 16 to 19, presented new opportunities for scientific interaction amongst HEOR...

Read article

November 5, 2020

Role of RWA in Transforming Oncological Research

In oncology, many manufacturers go into niche indications, where there are very specific tumors, and then they opt for...

Read article

October 22, 2020

An Interview with Bart Heeg (Part 2): New Trends in HEOR

In this two-part blog series, we interview Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel...

Read article

October 20, 2020

Interview with Thomas Wilke: Health Economics/World Evidence Studies

In this interview with Thomas Wilke, Principal Scientist at Ingress-Health (a Cytel company), we talk to him about his...

Read article

October 14, 2020

The Increasing Importance of Health Economics

A credible evidence base is needed to support and document the economic value of new technologies and therapeutic...

Read article

October 13, 2020

Introducing Observational Studies – Three Trends for Statisticians

The combination of greater access to electronic health records, bigger electronic claims datasets, and the need for...

Read article